期刊文献+

浸润性膀胱癌不同治疗方案预后的Meta分析 被引量:2

Meta Analysis of Prognosis for Patients with Invasive Bladder Cancer after Receiving Two Different Therapy Programs
下载PDF
导出
摘要 目的探讨保留膀胱手术后灌注化疗与膀胱全切术对浸润性膀胱癌预后的效果差异性。方法利用Medline、中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊数据库等,检索国内外已发表的相关文献并进行评估,提取资料后对行保留膀胱手术后灌注化疗或膀胱全切术的浸润性膀胱癌患者5年生存率进行Meta分析。结果计算两种治疗方案检验统计量Z=1.22,P=0.22,差异无统计学意义,总体相对危险度的95%可信区间为(0.94~1.29)。结论对于浸润性膀胱癌患者,局部切除加灌注化疗5年生存率与全切组无差别,可以谨慎地接受保留膀胱策略,提高患者生存质量。 Objective To explore the effects of two different therapy programs on prognosis of invasive bladder cancer patients.Methods Related papers in Medline,Chinese Biological Medicine Database,China Journal Fulltext Database and China Scientific Journal Database were searched,then these papers were assessed,and the 5-year survival rates of invasive bladder cancer patients after receiving bladder preserving resection plus systemic chemotherapy or radical cystectomy were analyzed by using Meta analysis.ResultsThe test statistics was Z=1.22,P=0.22,it was considered as "nonsignificant" result at the 5% level according to its P-value.Conclusion There is a no difference between bladder preserving resection plus systemic chemotherapy and radical cystectomy for invasive bladder cancer patients,and choosing a bladder reservation program modestly may be helpful for improve the patients′ living quality.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2012年第11期1357-1360,共4页 Cancer Research on Prevention and Treatment
基金 广州医学院博士启动资助项目(2011C48)
关键词 浸润性膀胱癌 膀胱切除术 化疗 META分析 Invasive bladder cancer Radical cystectomy Chemotherapy Meta analysis
  • 相关文献

参考文献9

  • 1Parkin DM.Pisani P. Ferlay J. Global cancer statistics] L]. CA Cancer J Clin.1999 .49( 1) :33-64.1.
  • 2Jemal AvSiegel R. Ward Ever al, Cancer statistics.2006[J]. CA Cancer J Clin.2006 .56(2): 106-30.
  • 3Solsona Ev Climent MA. Iborra I.et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy[J]. Eur Urol.2009. 55(4) :911-9.
  • 4Sternberg CN .Pansadoro V. Calabro F. et al. Can patient selection for bladder preservation be based on response to chemotherapy [J]. Cancer.2003.97(7): 1644-52.
  • 5Shipley WU Kaufman DS.Zehr Evet al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer[J]. urology ,2002 .60( 1) :62-8.
  • 6Rodel C, Grabenbauer GG. KUhn R. et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results [J]. J Clin Oncol , 2002. 20 (14): 3061-71.
  • 7Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer[J]. Eur Urol.2008.54(1) :126-32.
  • 8徐婷,刘光震,牛海涛.浸润性膀胱癌的综合治疗[J].现代泌尿生殖肿瘤杂志,2011,3(3):186-188. 被引量:1
  • 9Stenzl A. Cowan NC. De Santis M. et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer [n Eur Uroi.2009.55(4) :815-25.

二级参考文献26

  • 1Clark PE. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer[J]. Expert Rev Anticancer Ther, 2009,9(6):821-830.
  • 2Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer., update of a systematic review and meta-analysis of individual patient data[J]. Eur Urol,2005,48(2):202-205.
  • 3Black PC, Brown GA, Grossman HB, et al. Neoadjuvant chemotherapy for bladder cancer[J]. World J Urol,2006,24 (5) :531-542.
  • 4Winquist E, Waldron T, Segal R, et al. Neoadjuvant chemotherapy in transitional cell carcinoma of the bladder: a systematic review and meta-analysis[J]. J Urol,2004,171(2 Pt 1) :561-569.
  • 5Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a system atic review and meta-analysis of individual patient data Ad vanced Bladder Cancer (ABC) Meta-analysis Collaboration [J]. EurUrol,2005,48(2):189-201.
  • 6Apolo AB, Milowsky M, Bajorin DF. Clinical states model for biomarkers in bladder caneer[J]. Future Oneol, 2009,5 (7) :977-992.
  • 7Kaufman DS, Raghavan D, Carducci M, et al. Phase Ⅱ trial of gemcitabine plus cisplatin in patients with metastatic urotheIial cancer[J]. J Clin Oncol, 2000,18(9) : 1921-1927.
  • 8Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase [J] study of pemetrexed for second-line treatment of transitional cell cancerofthe urothelium[J]. J Clin 0ncol, 2006,24(21):3451-3457.
  • 9Pos F, Remeijer P. Adaptive management of bladder cancer radiotherapy[J]. Semin Radiat Oncol, 2010,20 (2) :116-120.
  • 10Ott OJ, R6del C, Weiss C, et al. Radiochemotherapy for bladder cancer[J]. Clin Oncol,2009,21(7):557-565.

同被引文献15

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部